Prognostic significance of HER2 expression in patients with resectable gastric cancer

Prognostic significance of HER2 expression in patients with resectable gastric adenocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN54802594

Enrollment

782

Registered

2018-09-11

Start date

2012-01-01

Completion date

Unknown

Last updated

2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenocarcinoma Cancer

Interventions

Among patients who underwent curative gastrectomy to treat gastric adenocarcinoma at Inje University Paik Hospital over four years, from January 2012 to December 2015, 782 patients underwent an immuno

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Among 810 patients who underwent curative gastrectomy to treat gastric adenocarcinoma at Inje University Busan Paik Hospital over four years, from January 2012 to December 2015, this study included 782 patients after excluding 28 patients who did not undergo IHC analysis

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
HER2 overexpression measured by immunohistochemical (IHC) analysis in gastric adenocarcinoma tissues obtained by curative gastrectomy at baseline	—

Secondary

Measure	Time frame
Clinicopathologic factors and survival rates collected from a gastric cancer database at August 2017	—

Countries

Korea, South

Contacts

Public ContactKwangHee Kim

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026